Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21064436 | 0.88 | APP (0.37) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL2861805 | 0.82 | PTGS1 (0.35) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL11148783 | 0.82 | — | — | |
| SCHEMBL1805336 | 0.75 | PTGS1 (0.45) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL8553873 | 0.74 | CYP2D6 (0.34) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL30026428 | 0.73 | PTGS1 (0.43) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL439388 | 0.73 | PTGS1 (0.35) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL918133 | 0.72 | APP (0.38) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL1979880 | 0.72 | — | — | |
| SCHEMBL11235593 | 0.71 | APP (0.33) | APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190291045-A1 | 1-Amino-2-Methyl-2-Propanol Derivatives | TPAT IP LLC | 2019-09-26 | — | — | US | disclosed |
| US-10307707-B2 | 1-amino-2-methyl-2-propanol derivatives | TPAT IP LLC | 2019-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10307707-B2 | 1-amino-2-methyl-2-propanol derivatives | PNMT, PKD1, PKD2 | PTGS1 1250/4885PDE4A 26/4885LMNA 1724/4885 |
| US-20190291045-A1 | 1-Amino-2-Methyl-2-Propanol Derivatives | PNMT, PKD1, PKD2 | PTGS1 1250/4885PDE4A 26/4885LMNA 1724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.